BOSTON– A bundle of eight measures was effective in improving the quality of rheumatoid arthritis care while reducing costs, Dr. Eric D. Newman reported at the annual meeting of the American College...
BOSTON – Improvements in pain, stiffness, and physical function that occur with the addition of exercise therapy or manual therapy to usual care for patients at all stages of osteoarthritis extended...
Both male and female veterans were more likely to have arthritis than were nonveterans, according to a study from the Centers for Disease Control and Prevention.
For male veterans, the...
LAS VEGAS – A twice-daily 30-mg dose of apremilast significantly improved moderate to severe nail, scalp, and palmoplantar psoriasis, compared with placebo, based on data from 411 adults in the...
VIENNA – Vedolizumab, a second-line biologic for treating patients who have ulcerative colitis or Crohn’s disease and don’t respond to an anti-tumor necrosis factor drug, is gaining traction...
VIENNA – Patients treated with an anti–tumor necrosis factor drug had a 5% annual rate of developing one or more psoriasiform skin lesions in a review of more than 400 patients who received these...
VIENNA – Patients treated with an anti–tumor necrosis factor drug had a 5% annual rate of developing one or more psoriasiform skin lesions in a review of more than 400 patients who received these...
SILVER SPRING, MD. – The human monoclonal antibody secukinumab is expected to be the first biologic that targets interleukin-17A to be approved by the agency for treating psoriasis, with a Food and...
Rheumatoid arthritis patients treated with the biologic tocilizumab and the Janus kinase inhibitor tofacitinib had significant changes to their lipid levels in a meta-analysis of randomized,...
An international team of researchers has identified biomarkers that may help pinpoint rheumatoid arthritis patients at risk of interstitial lung disease.
Dr. Juan Chen of the First Hospital of...